Salmonella: A Promising Tool in Vaccine Development and Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (10 April 2024) | Viewed by 1137
Special Issue Editor
Interests: veterinary vaccines; delivery systems; Salmonella vectored vaccines; Salmonella in cancer therapy; oral mRNA vaccine; Salmonella pathophysiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The ability of live attenuated Salmonella to encode and deliver several classes of recombinant antigens to its host is being leveraged in the repurposing of bacteria as a vaccine vector against numerous infectious diseases and cancer. Heterologous antigens expressed by Salmonella can be delivered to specific subcellular locations in host cells via the manipulation of T3SS effector proteins. Furthermore, the ability to directly deliver antigens to professional APCs results in the elicitation of potent cellular immune responses through prominent CD8+ T cell priming.
Bacteria-based cancer therapy is a versatile platform that can be engineered as a standalone or combined with other therapies to improve prognosis in cancer. With its immunostimulatory property and ability to grow in hypoxic and immunosuppressive tumor microenvironments, Salmonella can direct immune responses toward tumors. When administered as a standalone, it either upregulates inflammasome pathways or promotes TNF-α mediated hemorrhage, which results in tumor necrosis. Salmonella can be genetically modified to encode and deliver an array of molecules that might be otherwise toxic if administered systemically, including pro-drugs, small interfering RNAs, nanobodies, toxins, and immunomodulators.
Therefore, through the use of Salmonella-mediated vaccine delivery in treating infectious diseases and cancer, it is expected that the limitations of conventional therapies, such as off-target toxicities and poor bioavailability, can be overcome.
For this Special Issue, we invite the submission of original research articles, communications, and reviews that describe the potential use of Salmonella as a biological delivery vehicle for the therapy of cancer and infectious diseases.
We look forward to receiving your contributions.
Prof. Dr. John Hwa Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Salmonella
- Salmonella-vectored vaccines
- recombinant vaccine
- Salmonella-mediated cancer therapy
- novel delivery systems
- mucosal delivery
- Immune response
- delivery of DNA
- controlled release systems
